NASDAQ:CHRS Coherus BioSciences - CHRS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.40 -0.09 (-1.06%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.19▼$8.5350-Day Range$5.69▼$10.5252-Week Range$5.58▼$14.11Volume521,909 shsAverage Volume1.21 million shsMarket Capitalization$653.35 millionP/E RatioN/ADividend YieldN/APrice Target$16.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Coherus BioSciences MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside96.4% Upside$16.50 Price TargetShort InterestBearish13.97% of Float Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews Sentiment1.01Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.87) to ($1.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector366th out of 1,027 stocksBiological Products, Except Diagnostic Industry58th out of 169 stocks 3.3 Analyst's Opinion Consensus RatingCoherus BioSciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, Coherus BioSciences has a forecasted upside of 96.4% from its current price of $8.40.Amount of Analyst CoverageCoherus BioSciences has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.97% of the float of Coherus BioSciences has been sold short.Short Interest Ratio / Days to CoverCoherus BioSciences has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Coherus BioSciences has recently increased by 2.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCoherus BioSciences does not currently pay a dividend.Dividend GrowthCoherus BioSciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCoherus BioSciences has received a 69.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Coherus BioSciences is -1.08. Previous Next 2.8 News and Social Media Coverage News SentimentCoherus BioSciences has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Coherus BioSciences this week, compared to 2 articles on an average week.Search Interest23 people have searched for CHRS on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Coherus BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus BioSciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.45% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Coherus BioSciences are expected to grow in the coming year, from ($3.87) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus BioSciences is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus BioSciences is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoherus BioSciences has a P/B Ratio of 6.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Coherus BioSciences (NASDAQ:CHRS) StockCoherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.Read More Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Stock News HeadlinesJanuary 31, 2023 | seekingalpha.comCoherus BioSciences: Biosimilar Specialist With Approval Shot For Chinese Cancer Drug Looks Like A BuyJanuary 27, 2023 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) Trading Down 5.3%February 6, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." January 26, 2023 | reuters.comCHRS.O - | Stock Price & Latest News | ReutersJanuary 25, 2023 | seekingalpha.comCHRS Coherus BioSciences, Inc.January 18, 2023 | msn.comJunshi's toripalimab meets main goal of late-stage study in lung cancer subtypeJanuary 9, 2023 | finanznachrichten.deCoherus BioSciences, Inc.: Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea Biosimilar FYB203 from Klinge BiopharmaJanuary 9, 2023 | msn.comCoherus stock dips amid deal to acquire US rights to Eylea biosimilar FYB203February 6, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." January 9, 2023 | finance.yahoo.comCoherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge BiopharmaJanuary 4, 2023 | finance.yahoo.comCoherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | finance.yahoo.comShould You Invest in Coherus BioSciences (CHRS)?December 25, 2022 | markets.businessinsider.comCoherus : FDA Delays Action On BLA For Toripalimab As Treatment For Nasopharyngeal CarcinomaDecember 25, 2022 | finance.yahoo.comJunshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)December 24, 2022 | tmcnet.comCoherus and Junshi Biosciences Share Update on theDecember 24, 2022 | finance.yahoo.comCoherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)December 23, 2022 | msn.comCoherus sheds 13% on FDA action date for cancer drugDecember 21, 2022 | finance.yahoo.comWith 74% institutional ownership, Coherus BioSciences, Inc. (NASDAQ:CHRS) is a favorite amongst the big gunsNovember 10, 2022 | finance.yahoo.comCoherus BioSciences Third Quarter 2022 Earnings: Misses ExpectationsNovember 9, 2022 | seekingalpha.comCoherus BioSciences, Inc. (CHRS) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | finance.yahoo.comCoherus BioSciences Reports Third Quarter 2022 Results and Provides Business UpdateNovember 8, 2022 | finance.yahoo.comCoherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue EstimatesNovember 7, 2022 | msn.comCoherus BioSciences Earnings PreviewNovember 1, 2022 | finance.yahoo.comCoherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022October 18, 2022 | finance.yahoo.comInvestors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 55% over the last three yearsOctober 12, 2022 | marketwatch.comCoherus, Junshi Publish Positive Results From Toripalimab StudyOctober 12, 2022 | finance.yahoo.comCoherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical OncologySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Company Calendar Last Earnings11/08/2022Today2/06/2023Next Earnings (Estimated)2/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS CUSIPN/A CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees332Year Founded2010Price Target and Rating Average Stock Price Forecast$16.50 High Stock Price Forecast$30.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+96.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-287,100,000.00 Net Margins-116.54% Pretax Margin-116.54% Return on Equity-422.10% Return on Assets-47.03% Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.45 Sales & Book Value Annual Sales$326.55 million Price / Sales2.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book6.61Miscellaneous Outstanding Shares77,780,000Free Float68,515,000Market Cap$653.35 million OptionableOptionable Beta0.88 Social Links Key ExecutivesDenny M. LanfearChairman, President & Chief Executive OfficerMcDavid StilwellChief Financial OfficerVladimir VexlerChief Scientific OfficerRichard L. HameisterChief Technical OfficerRosh DiasChief Medical OfficerKey Competitors4D Molecular TherapeuticsNASDAQ:FDMTImmaticsNASDAQ:IMTXScholar RockNASDAQ:SRRKEditas MedicineNASDAQ:EDITFate TherapeuticsNASDAQ:FATEView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 1,381 shares on 2/2/2023Ownership: 0.023%Simplex Trading LLCSold 34,700 shares on 2/2/2023Ownership: 0.000%Legato Capital Management LLCBought 59,038 shares on 2/1/2023Ownership: 0.076%Wolverine Asset Management LLCBought 9,100 shares on 2/1/2023Ownership: 0.000%Sargent Investment Group LLCSold 3,970 shares on 1/31/2023Ownership: 0.014%View All Institutional Transactions CHRS Stock - Frequently Asked Questions Should I buy or sell Coherus BioSciences stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHRS shares. View CHRS analyst ratings or view top-rated stocks. What is Coherus BioSciences' stock price forecast for 2023? 4 brokerages have issued 1 year price objectives for Coherus BioSciences' shares. Their CHRS share price forecasts range from $7.00 to $30.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 96.2% from the stock's current price. View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts. How have CHRS shares performed in 2023? Coherus BioSciences' stock was trading at $7.92 at the beginning of 2023. Since then, CHRS stock has increased by 6.2% and is now trading at $8.41. View the best growth stocks for 2023 here. When is Coherus BioSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023. View our CHRS earnings forecast. How were Coherus BioSciences' earnings last quarter? Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its earnings results on Tuesday, November, 8th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.79) by $0.32. The biotechnology company had revenue of $45.42 million for the quarter, compared to analysts' expectations of $57.23 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 116.54%. What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO? 21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Coherus BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX). What is Coherus BioSciences' stock symbol? Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS." Who are Coherus BioSciences' major shareholders? Coherus BioSciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.44%), Scout Investments Inc. (0.85%), Legato Capital Management LLC (0.08%), Yousif Capital Management LLC (0.05%), Allspring Global Investments Holdings LLC (0.05%) and Comerica Bank (0.05%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler. View institutional ownership trends. How do I buy shares of Coherus BioSciences? Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Coherus BioSciences' stock price today? One share of CHRS stock can currently be purchased for approximately $8.41. How much money does Coherus BioSciences make? Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $654.13 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287,100,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. How many employees does Coherus BioSciences have? The company employs 332 workers across the globe. Does Coherus BioSciences have any subsidiaries? The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..Read More How can I contact Coherus BioSciences? Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com. This page (NASDAQ:CHRS) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.